Gefitinib (GFT)
Gefitinib is a drug used for certain breast, lung and other cancers. Gefitinib is an EGFR inhibitor, like erlotinib, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Gefitinib is the first selective inhibitor of epidermal growth factor receptor's (EGFR) tyrosine kinase domain. Thus gefitinib is an EGFR inhibitor. The target protein (EGFR) is a family of receptors which includes Her1(erb-B1), Her2(erb-B2), and Her 3(erb-B3). EGFR is overexpressed in the cells of certain types of human carcinomas - for example in lung and breast cancers. This leads to inappropriate activation of the anti-apoptotic Ras signalling cascade, eventually leading to uncontrolled cell proliferation. Research on gefitinib-sensitive non-small cell lung cancers has shown that a mutation in the EGFR tyrosine kinase domain is responsible for activating anti-apoptotic pathways.

Organism species: Pan-species (General)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Complete Antigen of Gefitinib (GFT) Antigenic Transformation Customized Service Offer
Antibodies n/a Monoclonal Antibody to Gefitinib (GFT) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Gefitinib (GFT) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Gefitinib (GFT) CLIA Kit Customized Service Offer
n/a ELISA Kit for Gefitinib (GFT) ELISA Kit Customized Service Offer